$EQ News

Piper Sandler Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $20

Analysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504

Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease - Slideshow

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

Leerink Partners Upgrades Equillium to Outperform, Raises Price Target to $6

Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis

Equillium Inc. (NASDAQ:EQ) Reports Narrower Q1 Loss But Slight EPS Miss as EQ504 Study Timeline Confirmed

Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights

Equillium Q1 EPS $(0.06) Misses $(0.05) Estimate

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event

Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

B. Riley Securities Initiates Coverage On Equillium with Buy Rating, Announces Price Target of $6

Raymond James Initiates Coverage On Equillium with Strong Buy Rating, Announces Price Target of $6

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Cantor Fitzgerald Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $10